Meningococcal Vaccine Market, By Type (Bivalent, Quadrivalent and Others), By Brand (Menactra, Menveo, Nimenrix, Trumenba, Bexsero and Others) By Age group ( Infants (0 to 2 year), Children & Adult( 2 or Above), By Distribution (Government and Private), By Vaccine( Polysaccharides, Conjugate, Protein based vaccines), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI461921 | Publish Date: May 2023 | No. of Pages: 192

Global Meningococcal Vaccine Market Overview

Meningococcal meningitis (also known as bacterial meningococcal meningitis and epidemic cerebrospinal meningitis) is a form of meningitis caused by a specific bacterium known as Neisseria meningitidis. The bacterium is spread by droplets in the air or close contact with an infected person. Neisseria meningitidis collects in the nasopharynx, or post-nasal space, that connects the nasal cavities with the throat and then this bacterium is transported to the membranes (meninges) around the brain or spinal cord by the blood. It usually spreads from nearby infected areas such as the nasal sinuses or from the cerebrospinal fluid. Meningitis is characterized by inflammation of the membranes (meninges) around the brain or spinal cord. This inflammation can begin suddenly (acute) or develop gradually (sub-acute). Symptoms may include fever, headache, and a stiff neck, sometimes with aching muscles. Nausea, vomiting and other symptoms may also occur. Skin rashes occur in half of all individuals with meningococcal meningitis. Meningococcal meningitis is also associated with a high mortality rate and persistent neurological defects, particularly among infants and young children. Meningococcal meningitis without antibiotic therapy is uniformly fatal. Meningococcal Vaccine Market accounted for US$ 3.0 Billion in 2020 and is estimated to be US$ 7.4 Billion by 2030 and is anticipated to register a CAGR of 9.5%

Global Meningococcal Vaccine Market Dynamics

 

Rising inclusions in National Immunization Program (NIPs) by governments

Increasing immunization initiatives by government and regulatory authorities to combat the rising prevalence of meningitis is expected to boost the Global Meningococcal Vaccine Market. For instance, the Ministry of health, Government of Australia upgraded NIPs by including Nimenrix-quadrivalent ACWY vaccines to the national immunization program in Australia, thus pushing the sale of vaccines in February 2018.

Greater awareness results in higher demands

Surging healthcare awareness among children, teen and adolescent from getting infected by meningococcal disease points to an influx of opportunities for key players. Increasing number of individual becoming aware regarding this disease triggers the global market, especially worst-hit region.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Meningococcal Vaccine Market Segmentation

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Meningococcal Vaccine Market is segmented based on type, brand, age-group, distribution and region. On the basis of type, the Global Meningococcal Vaccine Market is segmented into Bivalent, Quadrivalent and Others. Based on brands, the target market is segmented into Menactra, Trumenba, Menveo, Bexsero, Nimenrix and others. On the basis of age-group, the target market is segmented into Infants (0-2 years) and Children & Adult (2 years or above). On the basis of distribution, the market is segmented in Private and Government. On the basis of vaccines, market is segmented in polysaccharides, conjugate, protein based vaccines.

Regional Insights:

Based on region, the Global Meningococcal Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market and accounted with revenue share of 47.9% in 2019 followed by Europe. High support from government and investment in R&D are the driving factors for North America. Several multivalent, conjugate vaccines by Indian and Chinese manufacturers are in the pipeline and if approved and commercialized in other geographies, could increase global access. With several developing countries, including BRICS (Brazil, Russia, India, China, and South Africa) taking significant steps to initiate the development and production of effective treatments, opportunities for manufacturers in these regions are likely to double in the near future. Partnership between key players and leading companies in BRICS countries are likely to boost the Global Meningococcal Vaccine Market.

In AsiaPacific, the market is expected to grow significantly owing to the increasing pediatric population and increasing initiatives from government for the meningococcal vaccines.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Type- Bivalent, Quadrivalent and Others

By Brand– Menactra, Menveo, Bexsero, Trumenba, Nimenrix and Others.

By Age group– Infants(0-2 years), Children & Adults(2 year or above)

By Distribution- Private and Government

By Vaccine- Polysaccharides, Conjugate, Protein based vaccines

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented Global Meningococcal Vaccine Market report based on type, brand, age-group, distribution, vaccine and region.

Global Meningococcal Vaccine Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Meningococcal Vaccine Market Key Players

The key players operating in the Global Meningococcal Vaccine Market include Pfizer Inc., Serum Institute of India ltd., Novartis AG, Sanofi, GlaxoSmithKline plc., Merck & Co., Inc. On 19th August 2020 GSK announced first participate vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine. Serum Institute of India is working on a thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) for developing countries. Also, the U.S. Food and Drug Administration (FDA) has agreed to review Sanofi’s meningococcal vaccine candidate, MenQuadfi. Previously, in April 2018, Pfizer’s meningococcal vaccine TRUMENBA received the Breakthrough Therapy designation from U.S. FDA for use in children aged 1 to 9 years.

Pfizer has developed a new molecular entity named PF-06886992 for Serogroups ABCWY Meningococcal Infections which is currently in Phase II clinical trials.

Global Meningococcal Vaccine Market Company Profile

Company Profile:

  • Serum Institute of India ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • GlaxoSmithKline plc.
  • Merk & co., Inc.

 “*” marked represents similar segmentation in other categories in the respective section

Global Meningococcal Vaccine Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Meningococcal vaccine Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, Brand
      • Market Snippet, By Age-group
      • Market Snippet, By Distribution
      • Market Snippet, By Vaccine
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Meningococcal Vaccine Market, By Type 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Bivalent
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Quadrivalent
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Other
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Meningococcal Vaccine Market, By Brand 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Menactra
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Menveo
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Nimenrix
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Trumenba
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Bexsero
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  1. Global Meningococcal Vaccine Market, By Age-group, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Infants
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Children and Adult
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  2. Global Meningococcal Vaccine Market, By Distribution, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Government
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Private
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  3. Global Meningococcal Vaccine Market, By Vaccine, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Polysaccharides
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Conjugate
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Protein based vaccines
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  1. Global Meningococcal Vaccine Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Brand, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Age-group, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Vaccine, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
      •  – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Brand, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Age-group, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Vaccine, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Brand, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Age-group, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Vaccine, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Brand, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Age-group, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Vaccine, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Brand, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Age-group, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Vaccine, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Serum Institute of India ltd.
    • Company Overview
    • Product Portfolioa
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • GlaxoSmithKline plc.
  • Merck & co., Inc.
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

Meningococcal Vaccine Market accounted for US$ 3.0 Billion in 2020 and is estimated to be US$ 7.4 Billion by 2030 and is anticipated to register a CAGR of 9.5%.

The meningococcal vaccine market is segmented based on the type, brand, age-group, vaccine and region.

the development of multivalent vaccines, increased focus on vaccination programs in high-risk populations, and advancements in vaccine technologies, presenting significant opportunities in the global Meningococcal Vaccine Market.

rising incidence of meningococcal disease, the implementation of vaccination programs, growing awareness about preventive healthcare, and advancements in vaccine research and development.

North America, Europe, and Asia-Pacific are likely to be key regions, but the situation is dynamic, and it's advisable to refer to the latest reports for the most current information.

The key players operating in the global meningococcal vaccine market include Pfizer Inc., Serum Institute of India ltd., Novartis AG, Sanofi, GlaxoSmithKline plc. , Merck & o., Inc.